Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca Pulls Twitter Ads, Showing Risks Of Expansive Social Media Platforms

This article was originally published in The Pink Sheet Daily

Executive Summary

Company thought sponsored messages on AP’s feed were unbranded, but realized drug name showed up in expanded tweet. Did intricacies of the platform produce an inadvertent violation?

You may also be interested in...



Social Media Marketing: FDA’s Old-Time Approach May Turn Industry Away

Draft guidances say tweets about a product must balance benefit and risk information, and firms cannot be selective in correcting information on third-party sites.

Social Media For Pharma: Focus On Building Community, Not Brands

Using social media as a marketing tool should be about building a community and not necessarily focused on brand marketing, Zoetis’ digital strategy manager tells conference attendees.

Keywords Not Major Advertising Enforcement Concern, FDA Says

FDA says keywords don’t need OPDP’s formal review, but that doesn’t mean they don’t have an opinion about how they’re used.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS076179

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel